| Summary of Financial Assets Recognized at Fair Value on Recurring Basis |
The Company’s financial assets recognized at fair value on a recurring basis consisted of the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, 2024 |
|
|
|
Total |
|
|
Level 1 |
|
|
Level 2 |
|
|
Level 3 |
|
|
|
(In thousands) |
|
Assets |
|
|
|
|
|
|
|
|
|
|
|
|
Cash equivalents and restricted cash equivalents |
|
$ |
66,898 |
|
|
$ |
66,898 |
|
|
$ |
- |
|
|
$ |
- |
|
Marketable securities: |
|
|
|
|
|
|
|
|
|
|
|
|
U.S. Treasury and other government-backed securities |
|
|
352,616 |
|
|
|
169,735 |
|
|
|
182,881 |
|
|
|
- |
|
Financial institution debt securities |
|
|
217,827 |
|
|
|
- |
|
|
|
217,827 |
|
|
|
- |
|
Corporate debt securities |
|
|
94,927 |
|
|
|
- |
|
|
|
94,927 |
|
|
|
- |
|
Other asset-backed securities |
|
|
7,178 |
|
|
|
- |
|
|
|
7,178 |
|
|
|
- |
|
Total marketable securities |
|
|
672,548 |
|
|
|
169,735 |
|
|
|
502,813 |
|
|
|
- |
|
Investment in Kyverna Therapeutics, Inc. |
|
|
4,390 |
|
|
|
4,390 |
|
|
|
- |
|
|
|
- |
|
Total assets |
|
$ |
743,836 |
|
|
$ |
241,023 |
|
|
$ |
502,813 |
|
|
$ |
- |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, 2023 |
|
|
|
Total |
|
|
Level 1 |
|
|
Level 2 |
|
|
Level 3 |
|
|
|
(In thousands) |
|
Assets |
|
|
|
|
|
|
|
|
|
|
|
|
Cash equivalents and restricted cash equivalents |
|
$ |
136,254 |
|
|
$ |
136,254 |
|
|
$ |
- |
|
|
$ |
- |
|
Marketable securities: |
|
|
|
|
|
|
|
|
|
|
|
|
U.S. Treasury and other government-backed securities |
|
|
382,308 |
|
|
|
120,556 |
|
|
|
261,752 |
|
|
|
- |
|
Financial institution debt securities |
|
|
246,119 |
|
|
|
- |
|
|
|
246,119 |
|
|
|
- |
|
Corporate debt securities |
|
|
97,408 |
|
|
|
- |
|
|
|
97,408 |
|
|
|
- |
|
Other asset-backed securities |
|
|
59,504 |
|
|
|
- |
|
|
|
59,504 |
|
|
|
- |
|
Total marketable securities |
|
|
785,339 |
|
|
|
120,556 |
|
|
|
664,783 |
|
|
|
- |
|
Total assets |
|
$ |
921,593 |
|
|
$ |
256,810 |
|
|
$ |
664,783 |
|
|
$ |
- |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|